Guggenheim Has Lowered Expectations for Valneva (NASDAQ:VALN) Stock Price

Valneva (NASDAQ:VALN) had its price objective trimmed by Guggenheim from $17.00 to $15.00 in a research report released on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Valneva in a report on Friday, March 21st.

Valneva Price Performance

Shares of Valneva stock opened at $7.16 on Monday. The firm has a market cap of $581.83 million, a PE ratio of -55.08 and a beta of 1.93. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The business has a 50-day moving average price of $6.51 and a 200 day moving average price of $5.60.

Valneva (NASDAQ:VALN) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The business had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. Sell-side analysts predict that Valneva will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA purchased a new position in Valneva SE (NASDAQ:VALN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 19,244 shares of the company’s stock, valued at approximately $84,000. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.